New hope for kidney cancer patients with liver spread: drug combo trial launches
NCT ID NCT07256223
First seen Dec 04, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs (envafolimab and lenvatinib) as the first treatment for people with clear cell kidney cancer that has spread to the liver. The goal is to see if the combo can shrink liver tumors and help patients live longer. About 30 adults aged 18-75 who have not had prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.